The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Medvedev V.E.

Peoples’ Friendship University of Russia

Kardashian R.A.

Peoples’ Friendship University of Russia

Frolova V.I.

Peoples’ Friendship University of Russia

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders

Authors:

Medvedev V.E., Kardashian R.A., Frolova V.I.

More about the authors

Views: 1667

Downloaded: 7


To cite this article:

Medvedev VE, Kardashian RA, Frolova VI. Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):101‑109. (In Russ.)
https://doi.org/10.17116/jnevro2024124061101

Recommended articles:
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Sleep diso­rders and onco­logical diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131
Features of cognitive impairment in bipo­lar affe­ctive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19
Reco­gnan (citicoline) in the correction of asthenic and anxiety-depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47
Anti­depressants in psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):126-132

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.